20020220
 Anxiety Drug Is Expected to Get Cheaper In Wake of Ruling on Bristol-Myers Patent   By By Paula L. Stepankowsky, The Wall Street Journal,  Feb 21, 2002  Like many other drug companies, Bristol-Myers Squibb is coping with the expiration of patents covering key drugs. The patent protecting BuSpar expired in November 2000, and Bristol-Myers tried to extend its monopoly by filing an additional patent.  Mylan announced on Tuesday that the U.S. District Court for the Southern District of New York ruled earlier this month that Mylan and [Watson]'s buspirone product doesn't infringe on the Bristol-Myers BuSpar patent.   
